bluuebunny/crossref_metadata_2025_split huggingface dataset:
Tracing the Evolution: A Comprehensive Bibliometric Analysis of Drug Interaction Clinical Studies
Authors: Li Lanping , Zhou Yushi , Ye Lika , Xie Zhihong 
Published: August 2024

AbstractThis study aims to meticulously map the bibliometric landscape of drug‐drug interactions (DDIs) in clinical research. This represents the first use of bibliometric analysis to comprehensively highlight the evolutionary trends and core themes in this critical field of pharmacology. An exhaustive bibliometric search was performed within the Web of Science Core Collection, aiming to comprehensively gather literature on DDIs in clinical settings. A combination of sophisticated analytical tools including DIKW, VOSviewer, and Citespace was utilized for an in‐depth exploration of bibliometric patterns and trends. Of the 3421 initially identified articles, 2622 were considered relevant. The analysis revealed a marked escalation in DDIs publications, with a peak observed in 2020. Five principal thematic clusters emerged: Safety and Adverse Reactions, Drug Metabolism and Efficacy, Disease and Drug Treatment, Research Methods and Practices, and Special Populations and Combined Medication. Key insights included the escalating significance of drug metabolism in pharmacokinetics, heightened focus on cardiovascular and antiviral therapeutics, and the advancing frontier of personalized medicine. Additionally, the analysis underscored the necessity for strategic attention to vulnerable populations and innovative methodological approaches. This study calls for the global harmonization of research methods in DDIs clinical investigations, advocating for the integration of personalized medicine paradigms and the implementation of cutting‐edge computational analytics. It highlights the imperative for inclusive and collaborative research approaches to adeptly address the intricate challenges of contemporary pharmacotherapy.
Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor
Authors: Hu Xiaotong , Lin Hongda , Huang Yan , Xu Pingsheng , Xu Bin , Yu Haibin , Wang Meixia , Feng Sheng , Li Yijing , Shen Kai 
Published: August 2024

AbstractThis parallel‐group, open‐label Phase I study evaluated the effect of mild to moderate hepatic impairment on pharmacokinetics (PK), pharmacodynamics (PD), and safety of a single oral dose of SHR4640. Participants with mild or moderate hepatic impairment were enrolled, with each cohort consisting of eight individuals, alongside eight well‐matched controls with normal hepatic function. The participants were administered 10 mg SHR4640, and blood samples were collected for PK evaluation over 72 h. Additionally, serum uric acid (sUA) levels were measured to assess PD changes. Safety was evaluated through adverse events, laboratory tests, vital signs, and electrocardiograms. The Cmax of SHR4640 decreased by 15.0% in the mild hepatic impairment group (geometric least squares means of the ratios [GMR] = 0.850, 90% CI: 0.701‐1.03) and by 17.5% in the moderate hepatic impairment group (GMR = 0.825, 90% CI: 0.681‐1.00). These reductions were not statistically significant compared to the normal hepatic function group. AUC0‐t and AUC0‐inf were similar across all groups, indicating that overall exposure to the drug was not clinical significantly affected by hepatic impairment. Apparent clearance and volume of distribution of SHR4640 showed no association with the severity of hepatic impairment as measured by the Child–Pugh score. There were no significant differences in the changes in sUA levels from baseline across different levels of hepatic function. SHR4640 is well tolerated in participants with mild or moderate hepatic impairment. Mild and moderate hepatic impairment did not have a clinically relevant impact on PK, PD, and safety of SHR4640. SHR4640 can be used in patients with mild to moderate hepatic impairment without the need for dose adjustment.
Biopotency and surrogate assays to validate the immunomodulatory potency of extracellular vesicles derived from mesenchymal stem/stromal cells for the treatment of experimental autoimmune uveitis
Authors: Kaur Gagandeep , Bae Eun‐Hye , Zhang Yu , Ciacciofera Nicole , Jung Kyung Min , Barreda Heather , Paleti Carol , Oh Joo Youn , Lee Ryang Hwa 
Published: August 2024

AbstractExtracellular vesicles (EVs) derived from mesenchymal stem/stromal cells (MSCs) have been recognized as promising cytotherapeutics due to their demonstrated immunomodulatory effects in various preclinical models. The immunomodulatory capabilities of EVs stem from the proteins and genetic materials they carry from parent cells, but the cargo contents of EVs are significantly influenced by MSC tissues and donors, cellular age and culture conditions, resulting in functional variations. However, there are no surrogate assays available to validate the immunomodulatory potency of MSC‐EVs before in vivo administration. In previous work, we discovered that microcarrier culture conditions enhance the immunomodulatory function of MSC‐EVs, as well as the levels of immunosuppressive molecules such as TGF‐β1 and let‐7b in MSC‐EVs. Building on these findings, we investigated whether TGF‐β1 levels in MSC‐EVs could serve as a surrogate biomarker for predicting their potency in vivo. Our studies revealed a strong correlation between TGF‐β1 and let‐7b levels in MSC‐EVs, as well as their capacity to suppress IFN‐γ secretion in stimulated splenocytes, establishing biopotency and surrogate assays for MSC‐EVs. Subsequently, we validated MSC‐EVs generated from monolayer cultures (ML‐EVs) or microcarrier cultures (MC‐EVs) using murine models of experimental autoimmune uveoretinitis (EAU) and additional in vitro assays reflecting the Mode of Action of MSC‐EVs in vivo. Our findings demonstrated that MC‐EVs carrying high levels of TGF‐β1 exhibited greater efficacy than ML‐EVs in halting disease progression in mice with EAU as well as inducing apoptosis and inhibiting the chemotaxis of retina‐reactive T cells. Additionally, MSC‐EVs suppressed the MAPK/ERK pathway in activated T cells, with treatment using TGF‐β1 or let‐7b showing similar effects on the MAPK/ERK pathway. Collectively, our data suggest that MSC‐EVs directly inhibit the infiltration of retina‐reactive T cells toward the eyes, thereby halting the disease progression in EAU mice, and their immunomodulatory potency in vivo can be predicted by their TGF‐β1 levels.
Comparison of EV characterization by commercial high‐sensitivity flow cytometers and a custom single‐molecule flow cytometer
Authors: Kim James , Xu Shihan , Jung Seung‐Ryoung , Nguyen Alya , Cheng Yuanhua , Zhao Mengxia , Fujimoto Bryant S. , Nelson Wyatt , Schiro Perry , Franklin Jeffrey L. , Higginbotham James N. , Coffey Robert J. , Shi Min , Vojtech Lucia N. , Hladik Florian , Tewari Muneesh , Tigges John , Ghiran Ionita , Jovanovic‐Talisman Tijana , Laurent Louise C. , Das Saumya , Gololobova Olesia , Witwer Kenneth W. , Xu Tuoye , Charest Al , Jensen Kendall Van Keuren , Raffai Robert L. , Jones Jennifer C. , Welsh Joshua A. , Nolan John P. , Chiu Daniel T. 
Published: August 2024

AbstractHigh‐sensitivity flow cytometers have been developed for multi‐parameter characterization of single extracellular vesicles (EVs), but performance varies among instruments and calibration methods. Here we compare the characterization of identical (split) EV samples derived from human colorectal cancer (DiFi) cells by three high‐sensitivity flow cytometers, two commercial instruments, CytoFLEX/CellStream, and a custom single‐molecule flow cytometer (SMFC). DiFi EVs were stained with the membrane dye di‐8‐ANEPPS and with PE‐conjugated anti‐EGFR or anti‐tetraspanin (CD9/CD63/CD81) antibodies for estimation of EV size and surface protein copy numbers. The limits of detection (LODs) for immunofluorescence and vesicle size based on calibration using cross‐calibrated, hard‐dyed beads were ∼10 PE/∼80 nm EV diameter for CytoFLEX and ∼10 PEs/∼67 nm for CellStream. For the SMFC, the LOD for immunofluorescence was 1 PE and ≤ 35 nm for size. The population of EVs detected by each system (di‐8‐ANEPPS+/PE+ particles) differed widely depending on the LOD of the system; for example, CellStream/CytoFLEX detected only 5.7% and 1.5% of the tetraspanin‐labelled EVs detected by SMFC, respectively, and median EV diameter and antibody copy numbers were much larger for CellStream/CytoFLEX than for SMFC as measured and validated using super‐resolution/single‐molecule TIRF microscopy. To obtain a dataset representing a common EV population analysed by all three platforms, we filtered out SMFC and CellStream measurements for EVs below the CytoFLEX LODs as determined by bead calibration (10 PE/80 nm). The inter‐platform agreement using this filtered dataset was significantly better than for the unfiltered dataset, but even better concordance between results was obtained by applying higher cutoffs (21 PE/120 nm) determined by threshold analysis using the SMFC data. The results demonstrate the impact of specifying LODs to define the EV population analysed on inter‐instrument reproducibility in EV flow cytometry studies, and the utility of threshold analysis of SMFC data for providing semi‐quantitative LOD values for other flow cytometers.
Analysis of seasonal H3N2 influenza virus epidemic characteristics and whole genome features in Jining City from 2018 to 2023
Authors: Jiang Yajuan , Dou Huixin , Wang Xiaoyu , Song Tongyun , Jia Yongjian , Yue Ying , Li Libo , He Feifei , Kong Lingming , Wu Zengding , Huang Xiankun , Liang Yumin , Jiao Boyan , Jiao Baihai 
Published: August 2024

AbstractSeasonal H3N2 influenza virus, known for its rapid evolution, poses a serious threat to human health. This study focuses on analyzing the influenza virus trends in Jining City (2018–2023) and understanding the evolving nature of H3N2 strains. Data on influenza‐like cases were gathered from Jining City's sentinel hospitals: Jining First People's Hospital and Rencheng Maternal and Child Health Hospital, using the Chinese Influenza Surveillance Information System. Over the period from 2018 to 2023, 7844 throat swab specimens were assessed using real‐time fluorescence quantitative PCR for influenza virus nucleic acid detection. For cases positive for seasonal H3N2 influenza virus, virus isolation was followed by whole genome sequencing. Evolutionary trees were built for the eight gene segments, and protein variation analysis was performed. From 2018 to 2023, influenza‐like cases in Jining City represented 6.99% (237 299/3 397 247) of outpatient visits, peaking in December and January. Influenza virus was detected in 15.67% (1229/7844) of cases, primarily from December to February. Notably, no cases were found in the 2020–2021 season. Full genome sequencing was conducted on 70 seasonal H3N2 strains, revealing distinct evolutionary branches across seasons. Significant antigenic site variations in the HA protein were noted. No resistance mutations to inhibitors were found, but some strains exhibited mutations in PA, NS1, PA‐X, and PB1‐F2. Influenza trends in Jining City saw significant shifts in the 2020–2021 and 2022–2023 seasons. Seasonal H3N2 exhibited rapid evolution. Sustained vigilance is imperative for vaccine updates and antiviral selection.
Microporous polysaccharide hemospheres for reducing pocket hematomas after cardiac device implantation in patients on antithrombotic therapy
Authors: Matsui Yuko , Higuchi Satoshi , Mori Fumiaki , Takehisa Kao , Kikuchi Kensuke , Kikuchi Haruka , Hirobe Kohei , Maeda Ryozo , Tsukamoto Kei , Saito Takashi , Shoda Morio , Yamaguchi Junichi 
Published: August 2024

AbstractBackgroundVarious surgical procedures have employed microporous polysaccharide hemosphere (MPH) hemostatic agents. However, data regarding their effectiveness in preventing pocket hematomas (PHs) during the implantation of cardiac implantable electronic devices (CIED) among the Asian population are limited. Therefore, this study aimed to investigate the potential benefits of using MPH hemostatic agents during CIED implantations as a preventive measure against post‐procedural PHs.MethodsWe conducted a retrospective, single‐center, observational study involving 255 consecutive Japanese patients who underwent CIED implantation between November 2017 and April 2021. We compared PH occurrences within 28 days after CIED implantation between patients who received MPH hemostatic agents (n = 145) and those who did not (n = 110).ResultsPH development was observed in nine (6.2%) patients who received MPH hemostatic agents and in 13 (11.8%) patients without MPH hemostatic (p = .111). Kaplan–Meier analysis of PH development revealed no significant difference between the two groups (log‐rank p = .102). However, utilizing MPH hemostatic agents among patients taking antithrombotic drugs, including antiplatelet medications, direct oral anticoagulants, and warfarin, significantly reduced PH incidence (log‐rank p = .03). The multivariate Cox proportional hazards model demonstrated that MPH hemostatic agent utilization independently correlated with a decreased PH risk (hazard ratio 0.22, 95% confidence interval 0.08–0.63, p = .004).ConclusionsThe findings of this study suggest that the incorporation of MPH hemostatic agents into standard practice may benefit to mitigate PH risk during CIED implantations in patients on antithrombotic therapy. This simple and practical measure may be valuable, especially in high‐risk patients, such as those taking antithrombotic medications.
Methotrexate and Rituximab Use in Highly Recurrent Idiopathic Subglottic Stenosis
Authors: Awadallah Andrew S. , Bowen Andrew J. , Ali Hawa M. , O'Byrne Thomas J. , Padilla Hannah M. , Khalil Yousuf H. , Aden Aisha A. , Edell Eric S. , Koster Matthew J. , Bayan Semirra L. , Ekbom Dale C. 
Published: August 2024

ObjectiveTo evaluate the impact of methotrexate and rituximab therapy on highly recurrent idiopathic subglottic stenosis (iSGS) patients with a negative antineutrophil cytoplasmic antibody titer cANCA(−).MethodsThis was a retrospective cohort study of highly recurrent iSGS patients who recurred within 1 year or less and were treated with methotrexate (MTX), and rituximab (RTX), or a combination of both at different time points (MTX/RTX). Average surgical durations before and after drug treatment were summarized, and the differences were calculated.ResultsA total of 21 female patients with median age of 62 years were included. Fifteen patients were treated with MTX, three were treated with RTX, and five treated with both. Patients treated with immunosuppressants showed a trend toward longer intervals between operations (mean pre‐drug interval: 338; mean post‐drug interval: 697 days) (p‐value = 0.25). Three patients did not recur following drug initiation with median follow‐up of 1265 days. All three treatment groups demonstrated a trend toward increased post‐drug recurrence intervals (MTX: 444 days, RTX: 374 days, MTX/RTX: 55 days), that was not statistically significant. Patients with prior dilations demonstrated longer post‐drug recurrence intervals (mean pre‐drug interval: 341 days, mean post‐drug interval 978 days) (p‐value = 0.17). Four patients in the cohort with the highest recurring disease improved from mean 129 days between operations to 509 days with drug therapy. The most common drug side effect was nausea (16%).ConclusionMTX and RTX may be treatment options for some highly recurrent iSGS patients. Initial results are variable and demonstrate a need for further research on drug candidacy.Level of Evidence3 Laryngoscope, 2024
Survival Outcomes of Transoral Microsurgery in T3/T4a Laryngeal Tumors: Systematic Review and Meta‐Analysis
Authors: Vasudevan Srivatsa Surya , Zulli Adam , Olinde Lindsay , Pang John , Nathan Cherie‐Ann O. , Asarkar Ameya A. 
Published: August 2024

ObjectiveTo critically evaluate oncological and functional outcomes following transoral laser microsurgery (TLM) in patients with T3/T4a glottic and supraglottic squamous cell carcinoma (SCC).Data SourcesA comprehensive search of five major databases—PubMed, Embase, Scopus, ScienceDirect, and Web of Science—was conducted using a combination of relevant keywords and MeSH terms.Review MethodsSystematic review and meta‐analysis of odds ratio (OR), hazards ratio (HR), and proportion, focusing on oncological and functional outcomes of TLM in advanced T3/T4a glottic and supraglottic tumors. A random‐effects meta‐analysis model was employed.ResultsThe review incorporated 29 cohort studies, representing a total of 1,897 patients undergoing TLM for T3/T4a glottic and supraglottic SCC. The cumulative 5‐year disease‐free survival (DFS) rate for T3 glottic and supraglottic tumors was 44.4% (95% CI: 47–66%) and 62.8% (95% CI: 63–81%), while the 5‐year DFS for T4 glottic and supraglottic tumors was 41.1% (95% CI: 33.4–49.2%) and 32.9% (95% CI: 19.3–50.1%), respectively. T3 glottic tumors exhibited a 2.5‐fold significantly higher odds of local recurrence post‐TLM compared to their T3 supraglottic tumors (95% CI: 1.6–3.9, p < 0.0001). Laryngeal preservation rates for T3glottic and supraglottic tumors were 68.9% (95% CI: 48.7–83.8%) and 88.4% (95% CI: 79.4–93.8%), respectively. Both groups showed comparable rates of tracheostomy (p = 0.48) and gastrostomy performed (p = 0.17).ConclusionsThis meta‐analysis suggests that TLM is a viable larynx preservation approach in select patients with T3/T4a glottic and supraglottic tumors. However, glottic tumors may have less favorable outcomes after TLM compared to those with advanced supraglottic tumors.Level of EvidenceN/A Laryngoscope, 2024 Laryngoscope, 2024
US public health surveillance, reimagined
Authors: Guralnik Elina 
Published: August 2024

AbstractIntroductionThis study presents two novel concepts for standardizing electronic health records (EHR)‐based public health surveillance through utilization of existing informatics methods and data platforms.MethodsDrawing from the collective experience in applied epidemiology, health services research and health informatics, the author presents a vision for an alternative path to public health surveillance by repurposing existing tools and resources, such as (1) computable phenotypes which have already been created and validated for a variety of chronic diseases of interest to public health and (2) large data platforms/collaboratives, such as All of Us Research Program and National COVID Cohort Collaborative. Opportunities and challenges are discussed regarding EHR‐based chronic disease surveillance, as well as the concept of phenotype definitions and large data platforms reuse for public health needs.Results/FrameworkReusing of computable phenotypes for EHR‐based public health surveillance would require secure data platforms and nationally representative data. Standardization metrics for reuse of previously developed and validated computable phenotypes are also necessary and are currently being developed by the author. This study presents a reimagined Learning Health System framework by incorporating Public Health and two novel concept sets of solutions into the healthcare ecosystem.Conclusion/Next StepsAlternative approaches to limited resources and current infrastructure of the US Public Health System, especially as applied to disease surveillance, are needed and may be possible when repurposing the resources and methodologies across the Learning Health System.
Study on corrosion resistance of arc sprayed Zn–xAl (x = 19, 27, and 37) pseudo alloy coatings in salt spray environment
Authors: Zhang Min , Wang Song , Li Qi , Liu Shifeng 
Published: August 2024

AbstractTo study the corrosion behavior of Zn–Al pseudo alloy coatings with different Al contents, Zn–xAl (x = 19, 27, and 37) pseudo alloy coatings were prepared by the wire arc spraying technique using Zn and Al wires with different diameters. This study investigated the microstructure, electrochemical corrosion behavior, and corrosion morphology and products of the as‐sprayed coatings after the salt spray test in 5 wt% NaCl solution. The results exhibited that the Zn–Al pseudo alloy coatings with higher Al content form denser corrosion products (Zn5(OH)8Cl2·H2O and Zn–Al layered double hydroxide) with stronger self‐shielding effect against corrosive media, thus provide better long‐term corrosion protection. Besides, electrochemical reactions are controlled by mass transfer until corrosion for 24 h, and then by a combination of mass transfer and diffusion for 96 h. Overall, it can be concluded that the Zn–37Al pseudo alloy coating in this study shows great potential to protect steel substrates from corrosion.
Narrowly Distributed Conjugated Polymers Synthesized Through Acid‐Catalyzed Aldol Polycondensations in Nanoreactors
Authors: Shi Huayu , Huang Xiaohua , Tian Donglai , Pan Huanghao , Hu Aiguo 
Published: August 2024

AbstractConjugated polymers are typically synthesized through transition metal‐mediated coupling reactions, which are often costly and have significant environmental impacts. Aldol condensation represents a more cost‐effective and sustainable synthetic technique for developing next‐generation organic functional materials. However, controlling the molecular weight and distribution of the resulting polymers remains challenging due to the uncontrollable step‐growth polymerization mechanism of aldol polycondensations. To this end, by selectively anchoring sulfonic acids inside the mesochannels of SBA‐15, the aldol polycondensation is exclusively confined within the pores. Experimental results demonstrate that this nanoreactor, by providing a spatially confined reaction environment, aids in controlling the progression of the polymerization and the growth of polymer chains, thereby achieving good control over polymer molecular weight and distribution, giving linear conjugated polymers and soluble conjugated polymeric nanoparticles with polymer dispersity down to 1.31.
Immunoglobulin class‐switch recombination: Mechanism, regulation, and related diseases
Authors: Liu Jia‐Chen , Zhang Ke , Zhang Xu , Guan Fei , Zeng Hu , Kubo Masato , Lee Pamela , Candotti Fabio , James Louisa Katherine , Camara Niels Olsen Saraiva , Benlagha Kamel , Lei Jia‐Hui , Forsman Huamei , Yang Lu , Xiao Wei , Liu Zheng , Liu Chao‐Hong 
Published: August 2024

AbstractMaturation of the secondary antibody repertoire requires class‐switch recombination (CSR), which switches IgM to other immunoglobulins (Igs), and somatic hypermutation, which promotes the production of high‐affinity antibodies. Following immune response or infection within the body, activation of T cell‐dependent and T cell‐independent antigens triggers the activation of activation‐induced cytidine deaminase, initiating the CSR process. CSR has the capacity to modify the functional properties of antibodies, thereby contributing to the adaptive immune response in the organism. Ig CSR defects, characterized by an abnormal relative frequency of Ig isotypes, represent a rare form of primary immunodeficiency. Elucidating the molecular basis of Ig diversification is essential for a better understanding of diseases related to Ig CSR defects and could provide clues for clinical diagnosis and therapeutic approaches. Here, we review the most recent insights on the diversification of five Ig isotypes and choose several classic diseases, including hyper‐IgM syndrome, Waldenström macroglobulinemia, hyper‐IgD syndrome, selective IgA deficiency, hyper‐IgE syndrome, multiple myeloma, and Burkitt lymphoma, to illustrate the mechanism of Ig CSR deficiency. The investigation into the underlying mechanism of Ig CSR holds significant potential for the advancement of increasingly precise diagnostic and therapeutic approaches.